At its meeting in November, ECHA’s Biocidal Products Committee (BPC) adopted four opinions on active substances and three opinions on Union authorisations.
Opinions Adopted on Active Substances
- Support for the renewal of Muscalure for product-type 19
- Non-support for the approval of Bromochloro-5,5-dimethylimidazolidine-2,4-dione for product-types 2, 11 and 12 due to a data gap concerning mutagenicity
- The Committee postponed its opinion on Ethanol to 2026
Opinions Adopted on Union Authorisations
Biocidal products or biocidal product families must be authorised by the European Commission in order to be made available on the market and used within the European Union and the European Economic Area. In this context, the biocidal product families for which a Union authorisation opinion was adopted in November are as follows:
- Biocidal product family containing Active chlorine released from hypochlorous acid for product-types 2, 4 and 5
- Biocidal product family containing Active chlorine released from sodium hypochlorite for product-type 4
- Biocidal product family containing Hydrogen peroxide for product-types 2 and 4
Opinions Adopted on Post-Authorisation Data
- Biocidal product family containing Permethrin; S-Methoprene for product-type 18
- Biocidal product family containing L-(+)-lactic acid for product-type 2
What Should Companies Do?
- To avoid the risk of applications being rejected due to insufficient data, it is necessary to minimize data gaps in application files, particularly regarding issues such as mutagenicity and endocrine-disrupting potential.
- Although the committee has postponed its decision on ethanol until May 2026, companies should be prepared for possible prohibitions or restrictions and assess alternatives to minimize possible market losses if such prohibitions are implemented.
The European Commission, together with the EU Member States, will take the final decisions on these opinions. Please stay tuned for updates.
